Vertex Pharmaceuticals Gets 96% of Product Sales From Treatments for 1 Disease. Here's Why That's About to Change.The Motley Fool · 1 day ago
Vertex Pharmaceuticals Incorporated (VRTX) Presents at American Society of Nephrology (ASN) Kidney Week 2026 TranscriptSeeking Alpha · 1 day ago
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 2026Business Wire · 2 days ago
Biotech Giants vs. Emerging Innovators: Which ETF Is the Better Buy?Fool - Investing News · 3 days ago
Vertex Pharmaceuticals (VRTX) Outpaces Stock Market Gains: What You Should KnowZacks Investment Research · 5 days ago
AbbVie vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?The Motley Fool · 5 days agoVertex Pharmaceuticals Incorporated is a leading biotechnology firm primarily focused on the discovery, advancement, and marketing of innovative treatments, particularly for cystic fibrosis (CF). The company offers a range of approved medications for CF patients, including SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO, which target specific mutations within the cystic fibrosis transmembrane conductance regulator gene. Additionally, they provide TRIKAFTA for individuals with CF aged six years and older who possess at least one F508del mutation.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 3, 2026 | $4.74 | $4.73 | Miss |
| May 4, 2026 | $4.24 | $4.47 | Beat |
| Feb 12, 2026 | $5.11 | $5.03 | Miss |
| Nov 3, 2025 | $4.57 | $4.80 | Beat |
| Aug 4, 2025 | $4.29 | $4.52 | Beat |
| May 5, 2025 | $4.25 | $4.06 | Miss |